Dr Valerie Stevenson

Books

Spasticity Management: A Practical Multidisciplinary Guide 2nd Edition (2016). Eds. VL Stevenson and L Jarrett. Taylor and Francis.

Spasticity Management: A Practical Multidisciplinary Guide (2006). Eds. VL Stevenson and L Jarrett. Informa Healthcare. ISBN 1-84184-560-4
Winner of the 2006 NHS Innovations Award (category: Publications/ DVD’s)

Book chapters

1. Stevenson VL, Miller DH. Measures of brain and spinal cord atrophy. Multiple Sclerosis Therapeutics. Martin Dunitz 1999. Editors Ruddick and Goodkin.

2. Stevenson VL, Miller DH, Rovaris M et al. A 1-year serial clinical and MRI study of primary progressive multiple sclerosis. Multiple Sclerosis: Tissue Destruction and Repair. Martin Dunitz 2000. Editors L Kappos, K Johnson, J Kesselring, EW Radu.

3. Stevenson VL. Monitoring disease progression in primary progressive multiple sclerosis. Frontiers in multiple sclerosis V. Martin Dunitz 2001. Editor M Clanet.

4. Gowland P, Stevenson VL. The measurement and clinical applications of T1 relaxation times. Quantitative MRI of the brain: measuring changes caused by disease. John Wiley & Sons 2003. Editor P Tofts.

5. Greenwood R, Stevenson VL, Marsden J, Playford ED, Thompson AJ. Neurorehabilitation. Eds. Clarke C, Howard R, Rossor M, Shorvon S. Neurology: A Queen Square Textbook. Blackwell Publishing, 2006.

6. Stevenson VL. Managing symptoms in MS. Eds. AJ Thompson. Neurological Rehabilitation in MS. Informa Healthcare, 2006.

7. Richard Greenwood, Diana Caine, Ulrike Hammerbeck, Alexander Leff, Diane Playford, Valerie Stevenson and Nick Ward. Restorative Neurology, Rehabilitation and Head Injury. Eds. Clarke C, Howard R, Rossor M, Shorvon S. Neurology: A Queen Square Textbook 2nd edition. Blackwell Publishing, 2016.

8. Stevenson VL. Management of spasticity in Neurorehabilitation. Eds. KPS Nair, M Gonzalez-Fernandez, JN Panicker. Neurorehabilitation Therapy and Therapeutics. Cambridge University Press, 2018

Journal articles

1. Stevenson VL, Playford ED, Langdon DW, Thompson AJ. Rehabilitation of incomplete spinal cord pathology: factors affecting prognosis and outcome. J Neurol 1996;243:644-647.

2. Stevenson VL, Acheson JF, Ball J, Plant GT. Optic Neuritis following measles/rubella vaccination in two thirteen year old children. BJ Ophth 1996;80:1110-1111.

3. Stevenson VL, Gawne-Cain ML, Barker GJ, Thompson AJ, Miller DH. Imaging of the spinal cord and brain in multiple sclerosis: a comparative study between fast FLAIR and fast spin echo. J Neurol 1997;244:119-124.

4. Stevenson VL, Moseley IF, Phatouros CC, MacManus D, Thompson AJ, Miller DH. Improved imaging of the spinal cord in multiple sclerosis using 3 dimensional fast spin echo. Neuroradiology 1998;40:416-419.

5. Stevenson VL, Leary SM, Losseff NA, Parker GJM, Barker GJ, Husmani Y, Miller DH, Thompson AJ. Spinal cord atrophy and disability in multiple sclerosis: a longitudinal study. Neurology 1998;51:234-238.

6. Stevenson VL, Thompson AJ. The management of multiple sclerosis; current and future therapies. Drugs of Today 1998;34(3):267-282.

7. Stevenson VL, Miller DH, Rovaris M, Barkhof F, Brochet B, de Sa J, Dousset V, Dousset V, Filippi M, Montalban X, Polman CH, Rovira A, Thompson AJ. Primary progressive and transitional progressive multiple sclerosis; a clinical and MRI cross sectional study. Neurology 1999;52(4):839-845.

8. Leary SM, Parker GJM, Stevenson VL, Barker GJ, Miller DH, Thompson AJ. Reproducibility of magnetic resonance imaging measurements of spinal cord atrophy: The role of quality assurance. Magn Reson Imaging 1999;17(5):773-776.

9. Camp SJ, Stevenson VL, Thompson AJ, Miller DH, Auriacombe S, Borras C, Brochet B, Comi G, Falautano M, Filippi M, Hérissé-Dulo L, Montalban X, Parrcira E, Polman CH, de Sa J, Langdon DW. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MR correlates. Brain 1999;122:1341-1348.

10. Leary SM, Stevenson VL, Miller DH, Thompson AJ. Problems in designing and recruiting to therapeutic trials in primary progressive multiple sclerosis. J Neurol 1999;246(7):562-568.

11. Leary SM, Davie CA, Parker GJM, Stevenson VL, Barker GJ, Miller DH, Thompson AJ. 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol 1999;246(11):1023-6.

12. Leary SM, Silver NC, Stevenson VL, Barker GJ, Miller DH, Thompson AJ. Magnetisation transfer of normal appearing white matter in primary progressive multiple sclerosis. Mult Scler 1999;5:313-316.

13. Stevenson VL, Miller DH. Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis. Mult Scler 1999;5:268-272.

14. Stevenson VL, Miller DH, Leary SM, Rovaris M, Barkhof F, Brochet B, Dousset V, Dousset V, Filippi M, Hintzen R, Montalban X, Polman CH, Rovira A, de Sa J, Thompson AJ. One year follow up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68:713-718.

15. Stevenson VL, Parker GJM, Barker GJ, Birnie K, Tofts PS, Miller DH, Thompson AJ. Quantification of T1 and T2 relaxation times in the normal appearing white matter and lesions of multiple sclerosis. J Neurol Sci 2000;178(2):81-87.

16. Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller DH, Polman CH, Stevenson VL, McDonald WI. Diagnostic criteria for primary progressive multiple sclerosis: A position paper. Ann Neurol 2000;47:831-835.

17. Fox NC, Jenkins R, Leary SM, Stevenson VL, Losseff NA, Crum WR, Harvey RJ, Rossor MN, Miller DH, Thompson AJ. Progressive cerebral atrophy in multiple sclerosis: a serial study using registered, volumetric MRI. Neurology 2000;54(4):807-12.

18. Weatherby SJM, Stevenson VL, Leary SM, Mann CLA, Fryer AA, Strange RC, Thompson AJ and Hawkins CP. No association between the APOE 4 allele and outcome and susceptibility in primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68(4):532.

19. Direkze NC, Stevenson VL, Schwartz MS, Wilson SG. Wriggling muscles as a sign of lung cancer. J R Soc Med 2000;93:373-374.

20. Lazeron RHC, Langdon DW, Filippi M, van Waesberghe JHTM, Stevenson VL, Boringa JBS, Origgi D, Thompson AJ, Falautano M, Polman CH, Barkhoff F. Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR. Mult Scler 2000;6(4):280-5.

21. Stevenson VL, Kennedy AM, Guiloff RJ. Idiopathic propriospinal myoclonus: a report of three cases. CPD Bulletin Neurology 2001;2(3):86-88.

22. Van der Putten JJ, Stevenson VL, Playford ED, Thompson AJ. Factors affecting functional outcome in patients with nontraumatic spinal cord lesions after inpatient rehabilitation.
Neurorehabil Neural Repair 2001;15(2):99-104.

23. Stevenson VL, Hardie RJ. Acanthocytosis and neurological disorders. J Neurol 2001;248:87-94.

24. Stevenson VL, Smith S, Matthews PM, Miller DH, Thompson AJ. Monitoring disease activity and progression in multiple sclerosis using MRI: sub-voxel registration for identification of lesion changes and to detect cerebral atrophy. J Neurol 2002:249(2);171-7.

25. Ingle GT, Stevenson VL, Miller DH, Leary SM, Rovaris M, Barkhof F, Brochet B, Dousset V, Filippi M, Montalban X, Polman CH, Rovira A, Thompson AJ. Two year follow up study of primary and transitional progressive multiple sclerosis. Mult Scler 2002:8(2);108-14.

26. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive multiple sclerosis: results of an exploratory double-blind, placebo-controlled trial. Neurology 2003;60:44-51.

27. Stevenson VL, Ferguson SM, Bain PG. Bickerstaff’s brainstem encephalitis, Miller Fisher syndrome and Guillain-Barre syndrome overlap with negative anti-GQ1b antibodies. Eur J Neurol 2003;10:187.

28. Stevenson VL, Plant GT. Acute ischaemic optic neuropathy in hypocalcaemia; metabolic cause or chance association? Neuro-ophthalmology 2001;26:265-270.

29. Hickman SJ, Coulon O, Parker GJ, Barker GJ, Stevenson VL, Chard D, Arridge SR, Thompson AJ, Miller DH. Application of a B-spline active surface technique to the measurement of cervical cord volume in multiple sclerosis from three-dimensional MR images. J Magn Reson Imaging. 2003;18(3):368-71.

30. Ingle GT, Stevenson VL, Miller DH, Thompson AJ. Primary progressive multiple sclerosis: a 5-year clinical and MRI study. Brain 2003;126(Pt 11):2528-36.

31. Stevenson VL, Ingle GT, Miller DH, Thompson AJ.Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study. Mult Scler. 2004 Aug;10(4):398-401.

32. Thompson AJ, Jarrett L, Lockley L, Marsden J, Stevenson VL. Clinical management of spasticity. J Neurol Neurosurg Psychiatry 2005;76(4):459-63.

33. Sastre-Garriga J, Ingle GT, Rovaris M, Tellez N, Jasperse B, Altmann DR, Benedetti B, Stevenson VL, Cercignani M, Leary SM, Barkhof F, Brochet B, Dousset V, Filippi M, Montalban X, Kalkers NF, Polman CH, Rovira A, Miller DH, Thompson AJ. Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. Neurology. 2005;65(4):633-5.

34. Camp SJ, Stevenson VL, Thompson AJ, Ingle GT, Miller DH, Borras C, Brochet B, Dousset V, Falautano M, Filippi M, Kalkers NF, Montalban X, Polman CH, Langdon DW. A longitudinal study of cognition in primary progressive multiple sclerosis. Brain. 2005;128(Pt 12):2891-8.

35. Leary SM, Gilpin P, Lockley L, Rodriguez L, Jarrett L, Stevenson VL. Intrathecal baclofen therapy improves functional intelligibility of speech in cerebral palsy, Clin Rehabil 2006;20(3):228-31.

36. Stevenson VL. Relief of symptoms in end-stage neurological conditions. Br J Hosp Med (Lond). 2007 Dec;68(12):640-3.

37. Stevenson VL, Playford ED. Rehabilitation and MS. Int MS J. 2007 Sep;14(3):85-92.

38. Dalton CM, Keenan E, Jarrett L, Buckley L, Stevenson VL. The safety of baclofen in pregnancy: intrathecal therapy in multiple sclerosis. Mult Scler. 2008 May;14(4):571-2.

39. Dalton C, Keenan E, Stevenson V. A novel cause of intrathecal baclofen overdosage: lessons to be learnt. Clin Rehabil. 2008 Feb;22(2):188-90.

40. Webb TE, Pal S, Siddique D, Heaney DC, Linehan JM, Wadsworth JD, Joiner S, Beck J, Wroe SJ, Stevenson V, Brandner S, Mead S, Collinge J. First report of Creutzfeldt-Jakob disease occurring in 2 siblings unexplained by PRNP mutation. J Neuropathol Exp Neurol. 2008 Sep;67(9):838-41.

41. Stevenson VL. Rehabilitation in practice: Spasticity Management. Clin Rehabil. 2010 Apr;24(4):293-304.

42. Erwin A, Gudesblatt M, Bethoux F, Bennett SE, Koelbel S, Plunkett R, Sadiq S, Stevenson VL, Thomas A-M, Tornatore C, Zaffaroni M, Hughes M. Intrathecal baclofen in multiple sclerosis: too little, too late? Mult Scler. 2011;17(5):623-629.

43. Marsden J, Ramdharry G, Stevenson V, Thompson A. Muscle paresis and passive stiffness: key determinants in limiting function in hereditary and sporadic spastic paraparesis. Gait and Posture, 2012;35(2):266-71.

44. Pritesh Bodalia, Kashyap Thakrar, Michael Scott, Val Stevenson and Anthony Grosso. Sativex for spasticity in MS. The British Journal of Clinical Pharmacy. 2011;3(3):79-81.

45. Stevenson VL, Playford ED. Neurological rehabilitation and the management of spasticity. Medicine 2012:40(9): 513-517.

46. Marsden J, Stevenson V, McFadden C, Swain I, Taylor P. The Effects of Functional Electrical Stimulation on Walking in Hereditary and Spontaneous Spastic Paraparesis. Neuromodulation 2013;16(3):256-60.

47. Marsden J, Stevenson V. Balance dysfunction in hereditary and spontaneous spastic paraparesis. Gait posture. 2013;38(4):1048-50.

48. Stevenson VL. Intrathecal baclofen in multiple sclerosis. Eur Neurol 2014;72(suppl 1):32–34.

49. Stevenson VL, Gras A, Bárdos J, Broughton J. The high cost of spasticity in multiple sclerosis to individuals and society. Mult Scler 2015 Oct;21(12):1583-92. doi: 10.1177/1352458514566416. Epub 2015 Jan 26.

50. Stevenson VL. Effective management of spasticity in patients with multiple sclerosis: improving quality of life and reducing costs. In: Managing spasticity in multiple sclerosis—a focus on the role of delta-9-tetrahydrocannabinol/cannabidiol. Guidelines in Practice 2015;18(4):supplement.

51. Wimalasundera N, Stevenson VL. Cerebral palsy. Pract Neurol. 2016 Feb 2. pii: practneurol-2015-001184. doi: 10.1136/practneurol-2015-001184. [Epub ahead of print]

52. A Quality Review of a Specialist Multidisciplinary Service Caring for People with Long-term Neurological Conditions/Spasticity. Elizabeth Keenan, Katrina Buchanan, Val Stevenson, Rachel Farrell, Heesook Lee, Gerry Christofi, Honey Padilla, Laura Bullass & Becky Jones. http://www.fons.org/Resources/Documents/Project%20Reports/A-Quality-Review-of-a-Specialist-Multidisciplinary-Service.pdf

53. Buchanan K, Christofi G, Farrell R, Keenan E and Stevenson VL. Botulinum Toxin Treatment in the Healing of Pressure Ulcers Resulting from Spasticity in Multiple Sclerosis. Phys Med Rehabil Int. 2017; 4(5): 1129.

54. Stevenson VL, Keenan E and Jarrett L. Troubleshooting Complications of Intrathecal Baclofen Therapy. Phys Med Rehabil Int. 2017; 4(4): 1126.

55. Simeoni S, Sparkes S, Keenan E, Buchanan K, Lee H, Padilla C, Stevenson V, Farrell R. Intrathecal Baclofen Preserves Walking Ability in Multiple Sclerosis Related Spasticity: A Case Report. Phys Med Rehabil Int. 2017; 4(4): 1127.

56. Simeoni S, Keenan E, Buchanan K, Lee H, Padilla C, Farrell R, Keenan E, Stevenson VL. Intrathecal Baclofen Pump Replacement: The Importance of Planning Ahead: A Case Report. Phys Med Rehabil Int. 2017; 4(5): 1128.

57. Hare N, Georgopoulos P, Philips KE, Johnson JE, Seary C, Panicker JN, Stevenson VL. Improvement in overactive bladder symptoms in patients using functional electrical stimulation of the common peroneal nerve for walking. Clinical Rehabilitation 2018, Vol. 32(10) 1357–1362.

58. Sammaraiee Y, Yardley M, Keenan L, Buchanan K, Stevenson V, Farrell R. Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience. Mult Scler Relat Disord. 2019;27:95-100.

59. Juckes F, Marceniuk G, Seary C, Stevenson VL. A cohort study of functional electrical stimulation in people with multiple sclerosis demonstrating improvements in quality of life and cost effectiveness. Clin Rehabil. 2019; 2019;33(7):1163-1170.

60. Balaratnam M.S., Donnelly A., Padilla H., Simeoni S., Bahadur S., Keenan L., Lee H., Farrell R., Curtis C., Brownstone R.M., Murphy M., Grieve J., Shieff C., Nayar M., Pitceathly R.D.S., Christofi G., Stevenson V.L. 2019. Reducing Intrathecal Baclofen Related Infections: Service Evaluation and Best Practice Guidelines. Neuromodulation 2019; E-pub ahead of print. DOI:10.1111/ner.13071

61. Stevenson VL, Playford D, Neurological rehabilitation and the management of spasticity, Medicine, https://doi.org/10.1016/j.mpmed.2020.06.003